ClinicalTrials.gg
RecruitingNCT07445997Updated Mar 3, 2026

The Association Between Preoperative HbA1c Levels and Postoperative Acute Kidney Injury in Isolated Coronary Artery Bypass Surgery

An observational study in Acute Kidney Injuries, Hemoglobin A1c Protein, Human and Coronary Bypass Graft Surgery, sponsored by Osman Sila Aydin. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Osman Sila Aydin · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 90 studies in Acute Kidney Injury with a site in Turkey — 21 open to participants now, 22 under way, none of them phase 3. Acute Kidney Injury · Turkey.

Planned enrollment
22nd of 73
200 · median 130
Started
2026
with 17 others
Observational
73 of 90
15 open now
Primary completion
2026-08
later than 7 of 21 live
Registered
66th of 90
by date

Among the 90 studies in Acute Kidney Injury with a site in Turkey, this one is the 22nd largest by planned enrollment of the 73 observational ones that give a count, is one of 18 that started in 2026, is one of 73 observational ones, reaches primary completion later than 7 of the 21 other live ones, and was the 66th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

21 of the 90 studies in Acute Kidney Injury with a site in Turkey are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Acute Kidney Injury with a site in Turkey, or all of them as a file.
02

Study summary

Renal complications are frequently encountered in cardiac surgery and constitute significant causes of morbidity and mortality. They most commonly present in the form of acute kidney injury (AKI). The etiological factors of AKI include hemodynamic alterations, hemolysis and pigment nephropathy, inflammatory response and cytokine storm, ischemia-reperfusion injury, use of nephrotoxic agents, patient-related risk factors (advanced age, diabetes mellitus, preoperative renal insufficiency, congestive heart failure, hypertension, anemia), duration of surgery, and postoperative complications such as low cardiac output syndrome, sepsis, bleeding and reoperation, hypoalbuminemia, and fluid imbalance.

Previous studies have demonstrated several mechanisms through which elevated HbA1c levels may contribute to acute renal injury, including glomerular damage and hyperfiltration, endothelial dysfunction and microvascular injury, tubular damage, accumulation of glycation products and advanced glycation end products (AGEs), structural changes in blood vessels, and metabolic and systemic factors.

The evaluation of acute renal failure relies on fundamental scoring systems, biomarkers, and imaging modalities. Among the scoring systems, the most current and widely used is the KDIGO (Kidney Disease: Improving Global Outcomes) classification. According to the KDIGO definition, the diagnosis of AKI can be established when at least one of the following three criteria is met: an increase in serum creatinine of ≥0.3 mg/dL within 48 hours, an increase in serum creatinine to ≥1.5 times baseline within 7 days, or a urine output of \<0.5 mL/kg/hour for more than 6 hours. AKI staging is performed based on these parameters.

Imaging modalities used in the assessment of renal function include renal ultrasonography (US), Doppler ultrasonography with measurement of the renal resistive index (RRI), renal MRI/MR angiography, and renal computed tomography (particularly CT angiography). RRI is a non-invasive, bedside-applicable method that provides direct information about renal vascular resistance by evaluating renal arterial flow patterns.

In our clinic, the rationale of the present study is to measure preoperative HbA1c and Doppler-derived RRI values in patients undergoing isolated coronary artery bypass surgery, and to evaluate their relationship with postoperative KDIGO classification and Doppler RRI values in order to gain insight into the development of AKI.

03

Conditions studied

  • Acute Kidney Injuries
  • Hemoglobin A1c Protein, Human
  • Coronary Bypass Graft Surgery
  • Renal Resistive Index

Browse trials for

Keywords

  • acute kidney injuries
  • hemoglobin A1c protein
  • coronary bypass graft surgery
  • renal resistive index
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

isolated coronary bypass graft surgery patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing isolated elective CABG surgery
  • Patients with available preoperative and postoperative Doppler RRI measurements
  • Patients with available data

Exclusion criteria

Exclusion Criteria:

  • Patients with chronic kidney disease
  • Emergency surgeries
  • Redo/revision surgeries
  • Patients undergoing concomitant valve surgery
  • Presence of acute infection or sepsis
  • Advanced heart failure (EF \<30%)
  • Requirement for intra-aortic balloon pump, pacemaker, or mechanical circulatory support
  • History of nephrectomy or single kidney
  • Preoperative serum creatinine >2.0 mg/dL
  • Pregnancy
  • Refusal to participate in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
7 Days
Patient registry
Yes

Groups and cohorts

  • isolated coronary bypass graft surgery patients
06

What researchers measure

Primary outcomes

  1. To evaluate the correlation between preoperative HbA1c Level, Doppler-Derived Renal Resistive Index (RRI), and development of acute kidney injury (KDIGO Criteria) after isolated coronary artery bypass grafting

    Preoperative HbA1c Level; Glycated hemoglobin level will be measured from blood samples preoperatively. Unit of Measure: Percentage (%) Measurement Tool:Standard laboratory high-performance liquid chromatography (HPLC) assay Preoperative and Postoperative Renal Resistive Index(RRI) RRI will be measured using Doppler ultrasonography from segmental or interlobar renal arteries. Unit of Measure: Dimensionless ratio (RRI value) Measurement Tool: Doppler ultrasonography Normal Value Reference: RRI \< 0.70 Outcome Measure Title: Incidence of Acute Kidney Injury (KDIGO Criteria) Acute kidney injury will be assessed according to KDIGO criteria. Unit of Measure: Incidence of AKI (% of patients meeting KDIGO criteria) AKI Stage (Stage 1-3 classification) Measurement Tool: Serum creatinine measurement (mg/dL) Urine output monitoring Definition: Increase in serum creatinine ≥0.3 mg/dL within 48 hours OR increase to ≥1.5 times baseline within 7 days OR urine output \<0.5 mL/kg/hour for ≥6 hours

    Time frame: Preoperative HbA1c Level Time Frame: Within 7 days prior to surgery Preoperative and Postoperative Renal Resistive Index (RRI) within 24 hours preoperatively and within 24 hours postoperatively KDIGO : 48 hours postoperatively,7 days postoperatively

Secondary outcomes

  1. To evaluate the correlation between preoperative HbA1c Level, Doppler-Derived Renal Resistive Index (RRI), and intensive care unit length of stay after isolated coronary artery bypass grafting

    Length of Stay in the Intensive Care Unit Description:Duration of postoperative stay in the intensive care unit. Unit of Measure: Days Measurement Tool: Hospital electronic medical records

    Time frame: Time Frame: From ICU admission after surgery until ICU discharge, up to one month

  2. To evaluate the correlation between preoperative HbA1c Level, Doppler-Derived Renal Resistive Index (RRI), and hospital length of stay after isolated coronary artery bypass grafting

    Total Hospital Length of Stay Description: Total duration of hospitalization following surgery. Unit of Measure: Days Measurement Tool: Hospital electronic medical records

    Time frame: Time Frame: From date of surgery until hospital discharge, up to 3 month

Other outcomes

  1. To evaluate the correlation between preoperative HbA1c level, Doppler-Derived Renal Resistive Index (RRI), and duration of mechanical ventilation after Isolated coronary artery bypass grafting

    Duration of Postoperative Mechanical Ventilation Description: Total duration of invasive mechanical ventilation following surgery. Unit of Measure: Hours Measurement Tool: Ventilator records and hospital electronic medical records

    Time frame: From ICU admission after surgery until successful extubation, up to one month

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Aug 2026, 7 months after the start.

Of 350 non-industry observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 7 months is below that.

Counting every sponsor, half of 365 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Mar 3, 2026
StartActual
Jan 20, 2026
Primary completionEst.
Aug 30, 2026
CompletionEst.
Aug 30, 2026
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07445997
Lead sponsor
Osman Sila Aydin
Responsible party
Osman Sila Aydin (anesthesiology and reanimation specialist, Bursa Sevket Yilmaz Training and Research Hospital) — Sponsor-investigator
First posted
Mar 3, 2026
Start date
Jan 20, 2026
Primary completion
Aug 30, 2026 (estimated)
Completion
Aug 30, 2026 (estimated)
Last update
Mar 3, 2026

Study contacts

OSMAN SILA AYDIN
Contact
osmansila@gmail.com
+(90)5059661014

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion